Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Defence Therapeutics Inc. (C:DTC)

Business Focus: Biotechnology & Medical Research (NEC)

INK Edge Outlook

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for DTC within the last 6 months
See all filings within the past 6 months

Company News

Jun 13, 2024 23:51 ET
Toronto, Ontario--(Newsfile Corp. - Le 13 juin/Jun 2024) - The quarterly rebalancing of the CSE 25 Index will result in the following changes, effective after the close on Friday, June 14, 2024.
Read full article
Jun 10, 2024 03:15 ET
Defence to Participate in 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting in Toronto on June 11, 2024
Vancouver, British Columbia--(Newsfile Corp. - June 10, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to announce its participation to the Society of Nuclear and Molecular Imaging ("SNMMI") annual meeting on June 11, 2024 at the Metro Toronto Convention Centre.
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
May 31, 202410,84310,249
May 15, 2024594-2,322
Apr 30, 20242,9161,582
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Defence Therapeutics Inc. is a Canada-based biotechnology company working on engineering vaccines and antibody drug conjugates (ADC) products using its proprietary platform. The Company is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. Its platform's core is the Accum technology, which enables delivery of vaccine antigens or ADCs in their intact form to target cells. The Company is focused on research, development and advancement of various products using its Accum technology, which include Dendritic Cell cancer vaccines using Accum (Accuvac); a new protein-based vaccine formulation against COVID and infectious diseases; ADC targeting various cancers; anti-cancer AccuTOX program; cervical cancer vaccine; mesenchymal stromal cell-based vaccine (ARM) targeting cancer, and messenger ribonucleic acid vaccination.

See business summary



Search (past week) for $DTC.CA

  • No tweets found